Study Shows Short-Term Gluten-Free Diet Improves Liver Health in MASLD Patients

Celiac.com 05/16/2024 - Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver condition often linked with metabolic syndrome. Lifestyle interventions have been the mainstay of management due to the lack of approved pharmacological treatments. One emerging area of interest is the role of wheat amylase trypsin inhibitors (ATI) in promoting intestinal and extra-intestinal inflammation, including liver fibrosis and insulin resistance.

The study focused on evaluating the impact of an ATI-free diet on metabolic dysfunction-associated steatotic liver disease (MASLD) through a 6-week randomized controlled trial. An ATI-free diet specifically eliminates wheat amylase trypsin inhibitors (ATIs), whereas a gluten-free diet avoids all sources of gluten, which includes ATIs but extends to other grains like barley and rye. The trial involved 45 patients, with 21 following an ATI-free diet and 24 on a balanced diet as per German Nutrition Society recommendations. Key parameters such as controlled attenuation parameter (CAP), body mass index (BMI), homeostatic model assessment of insulin resistance (HOMA-IR), and patient-reported outcomes (PROs) using the CLDQ-NASH questionnaire were assessed.

Key Findings and Implications

1. Significant Improvements: Patients on the ATI-free diet showed notable improvements in BMI, CAP, and HOMA-IR values, indicating better liver health and metabolic parameters compared to the control group.
2. Patient-Reported Outcomes: PROs assessed through the CLDQ-NASH questionnaire indicated better outcomes in the ATI-free diet group, emphasizing overall well-being benefits from the dietary intervention.
3. Implications for MASLD: The study suggests that short-term adoption of an ATI-free diet can lead to meaningful improvements in liver health and metabolic parameters in MASLD patients, offering a potential dietary approach for managing the condition.

Celiac.com Sponsor (A12):
In summary, results showed significant improvements in the ATI-free diet group compared to the control group. Patients on the ATI-free diet experienced reduced BMI, CAP, and HOMA-IR values, indicating improved liver health and metabolic parameters. Patient-reported outcomes also showed better outcomes in the ATI-free diet group, highlighting the overall well-being benefits of the dietary intervention.

Relevance to Celiac Disease

While the study primarily focused on MASLD, the findings have implications for individuals with celiac disease:

• Dietary Management: Similar to MASLD, celiac disease involves adverse reactions to gluten. The study's emphasis on the benefits of an ATI-free (gluten-free) diet underscores the importance of dietary management in celiac disease.
• Innovative Solutions: The study highlights the role of dietary interventions in improving liver health and overall well-being. For individuals with celiac disease, exploring gluten-free diets under healthcare guidance may provide valuable insights into managing their condition.
• Future Research: The positive outcomes seen in MASLD patients on an ATI-free diet could inspire further research into dietary approaches for celiac disease management, potentially leading to more tailored and effective interventions.

These findings suggest that short-term adoption of an ATI-free diet can lead to meaningful improvements in liver health, metabolic parameters, and patient-reported outcomes in MASLD patients. Further studies with larger sample sizes and longer durations are needed to validate these findings and explore additional biomarkers of dietary compliance and disease progression.

In conclusion, while directly focusing on MASLD, this study indirectly suggests promising avenues for dietary management in celiac disease, emphasizing the potential benefits of gluten-free diets for individuals with gluten-related conditions.

Read more in Alimentary Pharmacology & Therapeutics